Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant TC Plus Trastuzumab in HER2+ Early Breast Cancer
NCT00493649Phase 2Completed
- Sponsor
- US Oncology Network
- Start
- Jun 2007
- Primary completion
- Apr 2013
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cyclophosphamide and trastuzumab in breast cancer, sponsored by US Oncology Network. Primary endpoint: Disease-free Survival Rate at 2 years. Started Jun 2007; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00493649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00493649.